Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

European Journal of Cancer

Volumn 38, Issue 18, 2002, Pages 2407-2415

  De Jonge, M J A ^a   Verweij, J ^a   Van der Gaast, A ^a   Valota, O ^b   Mora, O ^c   Planting, A S Th ^a   Mantel, M A ^a   Van Den Bosch, S ^c   Lechuga, M J ^b   Fiorentini, F ^b   Hess, D ^d   Sessa, C ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Accelerated titration design; Cytotoxic; Thrombocytopenia

Indexed keywords

4 DEMETHOXY 3' DEAMINO 3' AZIRIDINYL 4' METHYLSULFONYLDAUNORUBICIN; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CYCLINE; DRUG METABOLITE; PNU 159548; PNU 169884; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD TOXICITY; CALCULATION; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSPNEA; ERYTHEMA; FACE EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0036893583     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00492-6     Document Type: Article

References (17)

1. Marchini S., Gonzalez Paz O., Ripamonti M.et al. Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Anti-Cancer Drug Des.ign. 10:1995;641-653.
2. Bakker M., van der Graaf W.T.A., Groen H.J.M., Smit E.F., De Vries E.G.E. Anthracyclines- pharmacology and resistance, a review. Curr Pharm Des. 1:1995;133-144.
3. Priebe W., Van N.T., Burke T.G., Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decrease cardiotoxicity. Anti-Cancer Drugs. 4:1993;37-48.
4. Mariani M., Capolongo L., Suarato A.et al. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing Pgp-MDR or at-MDR. Invest New Drugs. 12:1994;93-97.
5. Suarato A., Angelucci F., Bargiotti A.et al. Synthesis and study of structure-activity relationship of new classes of anthracyclines. Priebe W. Anthracycline Antibiotics. New Analogues, Methods of Delivery and Mechanism of Action. Symposium Series 674. 1995;142-155 American Chemical Society, Washington.
6. Geroni C., Ripamonti M., Arrigoni C.et al. Pharmacological and toxicological aspects of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548). a novel antineoplastic agent Cancer Res. 61:2001;1983-1990.
7. Ripamonti M., Farao M., Rossi R., Geroni C. Synergistic antitumor effect of PNU-159548 in combination with CPT-11 against murine leukemia and human tumor models. Proc Am Assoc Cancer Res. 40:1999;589.
8. Geroni C, Ripamonti M, Rossi R, Trizio D. Synergistic combinations of PNU-159548 with other antitumor drugs. In Proc 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000, (A364): 116.
9. Marchini S., Damia G., Broggini M.et al. 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 61:2001;1991-1995.
10. Lipp H.P. Cardiotoxicity of cytotoxic drugs. Lipp H.P. Anticancer Drug Toxicity. 1999;471-488 Marcel Dekker, New York.
11. Schott B., Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 38:1989;4069-4074.
12. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxicic drug therapy from in vitro tests. Ann Oncol. 9:1998;357-364.
13. Simon R., Freidlin B., Rubinstein L., Arbuck S.G., Collings J., Christian M.C. Accelerated titration designs for phase I clinical trials in oncology. J Nat Cancer Inst. 89:1997;1138-1147.
14. Arbuck S.G. Workshop on phase I study design. Annals Oncol. 7:1996;567-573.
15. Common Toxicity Criteria, Version 2.0. Bethesda, MD, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute.
16. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
17. Breda M., Basileo G., Fonte G., Long J., James C.A. Determination of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin and its 13-hydroxy metabolite by direct injection of human plasma into a column-switching liquid chromatography system with mass spectrometric detection. J Chromatography A. 854:1999;81-92.